![Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers | Molecular Cancer | Full Text Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers | Molecular Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12943-022-01534-8/MediaObjects/12943_2022_1534_Fig1_HTML.png)
Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers | Molecular Cancer | Full Text
![New Trends and Future Opportunities in the Enzymatic Formation of C−C, C−N, and C−O bonds - Sangster - - ChemBioChem - Wiley Online Library New Trends and Future Opportunities in the Enzymatic Formation of C−C, C−N, and C−O bonds - Sangster - - ChemBioChem - Wiley Online Library](https://chemistry-europe.onlinelibrary.wiley.com/cms/asset/843841ce-562a-4bec-ad31-6fefdaf093a7/cbic202100464-fig-5015-m.jpg)
New Trends and Future Opportunities in the Enzymatic Formation of C−C, C−N, and C−O bonds - Sangster - - ChemBioChem - Wiley Online Library
![PDF) A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell PDF) A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell](https://i1.rgstatic.net/publication/315324589_A_randomized_open-label_multicenter_phase_II_study_evaluating_the_efficacy_and_safety_of_BTH1677_13-16_beta_glucan_Imprime_PGG_in_combination_with_cetuximab_and_chemotherapy_in_patients_with_advanced_/links/58cc9df8aca272335513cd14/largepreview.png)
PDF) A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell
![MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer - ScienceDirect MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S089865682100067X-gr1.jpg)
MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer - ScienceDirect
![The neutral rate of whole-genome duplication varies among yeast species and their hybrids | Nature Communications The neutral rate of whole-genome duplication varies among yeast species and their hybrids | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-021-23231-8/MediaObjects/41467_2021_23231_Fig1_HTML.png)
The neutral rate of whole-genome duplication varies among yeast species and their hybrids | Nature Communications
![JCM | Free Full-Text | Recurrence Kinetics after Laparoscopic Versus Open Surgery in Colon Cancer. A Meta-Analysis | HTML JCM | Free Full-Text | Recurrence Kinetics after Laparoscopic Versus Open Surgery in Colon Cancer. A Meta-Analysis | HTML](https://www.mdpi.com/jcm/jcm-10-04163/article_deploy/html/images/jcm-10-04163-g002-550.jpg)